Leads Biolabs，one of the portfolio companies of Shenzhen Capital Group, went public on the HKEX Main Board
July 25, 2025
On July 25, Nanjing Leads Biolabs Co., Ltd. (stock code: 09887.HK),one of the portfolio companies of Shenzhen Capital Group Co., Ltd. (hereinafter “SCGC”), accomplished its initial public offering on the main board of the Hong Kong Stock Exchange.
As a clinical-stage biotech firm, Leads Biolabs focuses on new therapies for tumors, autoimmune disorders and severe diseases. Supported by proprietary platforms and R&D strengths, it owns a differentiated pipeline including core product LBL-024 and 13 drug candidates. Its oncology lineup boasts huge potential for monotherapy and combination treatment.
